Neutrophil Extracellular Traps in Tumors and Potential Use of Traditional Herbal Medicine Formulations for Its Regulation
X Li, L Hu, A Naeem, S Xiao, M Yang… - International Journal …, 2024 - Taylor & Francis
Neutrophil extracellular traps (NETs) are extracellular fibers composed of deoxyribonucleic
acid (DNA) and decorated proteins produced by neutrophils. Recently, NETs have been …
acid (DNA) and decorated proteins produced by neutrophils. Recently, NETs have been …
[HTML][HTML] Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics
S Pedersen, KP Jensen, B Honoré, SR Kristensen… - Clinical proteomics, 2022 - Springer
Background Early detection of small cell lung cancer (SCLC) crucially demands highly
reliable markers. Growing evidence suggests that extracellular vesicles carry tumor cell …
reliable markers. Growing evidence suggests that extracellular vesicles carry tumor cell …
MPs-ACT, an assay to evaluate the procoagulant activity of microparticles
Y Gao, X Li, Y Qin, J Men, J Ren, X Li… - Clinical and Applied …, 2023 - journals.sagepub.com
The procoagulant effect of microparticles (MPs) contributes to hypercoagulability-induced
thrombosis. We provide preliminary findings of the MPs-Activated Clotting Time (MPs-ACT) …
thrombosis. We provide preliminary findings of the MPs-Activated Clotting Time (MPs-ACT) …
[HTML][HTML] Identifying metabolic alterations in newly diagnosed small cell lung cancer patients
S Pedersen, JB Hansen, RG Maltesen, WM Szejniuk… - Metabolism Open, 2021 - Elsevier
Background Small cell lung cancer (SCLC) is a malignant disease with poor prognosis. At
the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is …
the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is …
Preliminary investigation of elevated collagen and blood‐clotting markers as potential noninvasive biomarkers for small cell lung cancer
J Thorlacius‐Ussing, SR Kristensen… - Thoracic …, 2023 - Wiley Online Library
Background Small cell lung cancer (SCLC) is highly aggressive with limited therapeutic
options and a poor prognosis. Moreover, noninvasive biomarker tools for detecting disease …
options and a poor prognosis. Moreover, noninvasive biomarker tools for detecting disease …
Plasma Tissue Factor Activity in lung cancer patients predicts venous thrombo-embolism and poor overall survival
H Doubre, I Monnet, R Azarian, P Girard… - Research and Practice …, 2024 - Elsevier
Background Biomarkers to identify lung cancer (LC) patients with high risk of venous
thromboembolism (VTE) are needed. Objectives To evaluate the usefulness of plasma …
thromboembolism (VTE) are needed. Objectives To evaluate the usefulness of plasma …
[PDF][PDF] The Real Mechanisms of Emodin Treating Lung Cancer Based on System Pharmacology.
F Gao, G Yan, L Sun, H Xia, Z Guo, H Lin… - Eurasian Journal of …, 2023 - ejmo.org
In the world nowadays, cancer gradually becomes the first problem to public health and
seriously threatens human life due to the high mortality and recurrence. In modern medical …
seriously threatens human life due to the high mortality and recurrence. In modern medical …
Identifying metabolic alterations in newly diagnosed small cell lung cancer patients
P Shona, JB Hansen, RG Maltesen, WM Szejniuk… - 2021 - qspace.qu.edu.qa
BackgroundSmall cell lung cancer (SCLC) is a malignant disease with poor prognosis. At
the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is …
the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is …
[PDF][PDF] Metabolism Open
S Pedersen, JB Hansen, RG Maltesen, WM Szejniuk… - researchgate.net
Background: Small cell lung cancer (SCLC) is a malignant disease with poor prognosis. At
the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is …
the time of diagnosis most patients are already in a metastatic stage. Current diagnosis is …